Join the Oncology Voice Network. Join for Free
Types of Conferences MSLs Attend & How To Prepare...
Medical Science Liaisons conference strategies networking for MSLs MSL conference planning post-conference follow-up

Types of Conferences MSLs Attend & How To Prepare...


Share This Article


Summary

In this episode, George Lehman joins to discuss the strategic role of Medical Science Liaisons (MSLs) at conferences. The conversation covers the importance of conference attendance for professional development, the responsibilities MSLs hold, and effective networking strategies. George explains how MSLs decide which conferences to attend and emphasizes setting clear goals and deliverables. The episode also covers compliance in conference interactions, pre-conference planning, and best practices for post-conference follow-up. Balancing territory management with conference responsibilities is explored, concluding with final thoughts and a call to action for listeners to subscribe.

George Limen, Medical Liaison at Novo Nordisk discussed the types of conferences MSLs attend and how to prepare

George Shares….

πŸ‘‰ What are the types of conferences MSLs attend and why
πŸ‘‰ Who are the targets for MSLs and who do they meet
πŸ‘‰ What are the basic goals for MSLs to achieve at conferences 
πŸ‘‰ How do MSLs plan for events and what is the follow up routine like
πŸ‘‰ Who covers the territory and how do you balance the effort when meetings happen

Click for Source
Medical Science Liaisons, conference strategies, networking for MSLs, MSL conference planning, post-conference follow-up

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN